

BIOMARIN PHARMACEUTICAL INC

Form 4

March 17, 2017

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIENAIME JEAN JACQUES**

(Last) (First) (Middle)

**C/O BIOMARIN  
PHARMACEUTICAL INC., 770  
LINDARO ST.**

(Street)

**SAN RAFAEL, CA 94901**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol

**BIOMARIN PHARMACEUTICAL  
INC [BMRN]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**03/15/2017**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)  
**Chief Executive Officer**

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        |                           | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|--------|---------------------------|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount | (A) or (D) Price          |   |  |   |
| Common Stock                    | 03/15/2017 <sup>(1)</sup>            | 03/15/2017   | M                              |   | 5,000  | A \$ 17.33                | 211,364   | D  |   |
| Common Stock                    | 03/15/2017 <sup>(1)</sup>            | 03/15/2017   | S                              |   | 5,000  | D \$ 91.42 <sup>(2)</sup> | 206,364   | D  |   |
| Common Stock                    | 03/15/2017                           | 03/15/2017   | F                              |   | 15,690 | D \$ 92.5                 | 190,674   | D  |   |
| Common Stock                    | 03/16/2017 <sup>(1)</sup>            | 03/16/2017   | M                              |   | 5,000  | A \$ 71.33                | 195,674   | D  |   |

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

|                 |                           |            |   |       |   |                               |         |   |
|-----------------|---------------------------|------------|---|-------|---|-------------------------------|---------|---|
| Common<br>Stock | 03/16/2017 <sup>(1)</sup> | 03/16/2017 | S | 5,000 | D | \$<br>91.96<br><sup>(2)</sup> | 190,674 | D |
|-----------------|---------------------------|------------|---|-------|---|-------------------------------|---------|---|

|                 |  |  |  |  |  |  |         |   |   |
|-----------------|--|--|--|--|--|--|---------|---|---|
| Common<br>Stock |  |  |  |  |  |  | 182,801 | I | Shares held<br>by<br>Jean-Jacques<br>Bienaime<br>Family Trust |
|-----------------|--|--|--|--|--|--|---------|---|---|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)     | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) | 8. Amount<br>or<br>Number<br>of<br>Shares |
|---|---|---|---|---|---|--|---|---|
| Stock<br>Option<br>(Right to<br>buy<br>Common<br>Stock) | \$ 17.33  | 03/15/2017 <sup>(1)</sup>               | 03/15/2017  | M                                       | 5,000   | 12/07/2007 06/06/2017  | Common<br>Stock   | 5,000                                     |
| Stock<br>Option<br>(Right to<br>buy<br>Common<br>Stock) | \$ 17.33  | 03/16/2017 <sup>(1)</sup>               | 03/16/2017  | M                                       | 5,000   | 12/07/2007 06/06/2017  | Common<br>Stock   | 5,000                                     |

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BIENAIME JEAN JACQUES  
C/O BIOMARIN PHARMACEUTICAL INC.  
770 LINDARO ST.  
SAN RAFAEL, CA 94901

X

Chief Executive Officer

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

03/17/2017

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Trade made pursuant to a 10b5-1 plan executed on November 15, 2016.
- (2) All shares were sold at the same price.
- (3) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.